Fatal meningoencephalitis associated with Ebola virus persistence in two survivors of Ebola virus disease in the Democratic Republic of the Congo: a case report study
Daniel Mukadi-Bamuleka,François Edidi-Atani,Maria E Morales-Betoulle,Anaïs Legand,Antoine Nkuba-Ndaye,Junior Bulabula-Penge,Placide Mbala-Kingebeni,Ian Crozier,Fabrice Mambu-Mbika,Shannon Whitmer,Olivier Tshiani Mbaya,Lisa E Hensley,Richard Kitenge-Omasumbu,Richard Davey,Sabue Mulangu,Peter N Fonjungo,Michael R Wiley,John D Klena,Martine Peeters,Eric Delaporte,Johan van Griensven,Kevin K Ariën,Catherine Pratt,Joel M Montgomery,Pierre Formenty,Jean-Jacques Muyembe-Tamfum,Steve Ahuka-Mundeke,EBOV Persistence Study Group,Anja De Weggheleire,Gnakub N Soke,Raymond Pallawo,Gouressy Ibrahima,Victor Epaso Gelege,John Kombe-Ngwama,Grace Kahambwe-Ekoko,Mathias Mossoko Gbe,Pierre-Céleste Adikey Limne,Etienne Yuma-Kibondo,Eddy Kinganda-Lusamaki,Adrienne Amuri Aziza,Yannick Tutu Tshia N'kasar,Elias Mumbere Kalemekwa,Divine Kitsa-Mutsumbirwa,Noella Mulopo-Mukanya,Fyfy Mbelu-Matulu,Marie-Anne Kavira-Muhindo,Jacques Kwizera Sendegeya,Hugo Kavunga-Membo
DOI: https://doi.org/10.1016/S2666-5247(24)00137-X
Abstract:Background: During the 2018-20 Ebola virus disease outbreak in the Democratic Republic of the Congo, thousands of patients received unprecedented vaccination, monoclonal antibody (mAb) therapy, or both, leading to a large number of survivors. We aimed to report the clinical, virological, viral genomic, and immunological features of two previously vaccinated and mAb-treated survivors of Ebola virus disease in the Democratic Republic of the Congo who developed second episodes of disease months after initial discharge, ultimately complicated by fatal meningoencephalitis associated with viral persistence. Methods: In this case report study, we describe the presentation, management, and subsequent investigations of two patients who developed recrudescent Ebola virus disease and subsequent fatal meningoencephalitis. We obtained data from epidemiological databases, Ebola treatment units, survivor programme databases, laboratory datasets, and hospital records. Following national protocols established during the 2018-20 outbreak in the Democratic Republic of the Congo, blood, plasma, and cerebrospinal fluid (CSF) samples were collected during the first and second episodes of Ebola virus disease from both individuals and were analysed by molecular (quantitative RT-PCR and next-generation sequencing) and serological (IgG and IgM ELISA and Luminex assays) techniques. Findings: The total time between the end of the first Ebola virus episode and the onset of the second episode was 342 days for patient 1 and 137 days for patient 2. In both patients, Ebola virus RNA was detected in blood and CSF samples during the second episode of disease. Complete genomes from CSF samples from this relapse episode showed phylogenetic relatedness to the genome sequenced from blood samples collected from the initial infection, confirming in-host persistence of Ebola virus. Serological analysis showed an antigen-specific humoral response with typical IgM and IgG kinetics in patient 1, but an absence of an endogenous adaptive immune response in patient 2. Interpretation: We report the first two cases of fatal meningoencephalitis associated with Ebola virus persistence in two survivors of Ebola virus disease who had received vaccination and mAb-based treatment in the Democratic Republic of the Congo. Our findings highlight the importance of long-term monitoring of survivors, including continued clinical, virological, and immunological profiling, as well as the urgent need for novel therapeutic strategies to prevent and mitigate the individual and public health consequences of Ebola virus persistence. Funding: Ministry of Health of the Democratic Republic of the Congo, Institut National de Recherche Biomédicale, Infectious Disease Rapid Response Reserve Fund, US Centers for Disease Control and Prevention, US National Cancer Institute (National Institutes of Health), French National Research Institute for Development, and WHO.